Phase 3 clinical trial result of Hanmi Pharm’s ‘Rovelito’ registered at intern. journal
The Phase 3 clinical trial result of Hanmi Pharm’s hypertension and hyperlipidemia complex ‘Rovelito’ was registered at a SCI-level international academic journal.
On the 9th, Hanmi Pharm announced the Phase 3 clinical trial result of its hypertension and hyperlipidemia complex ‘Rovelito’ was re...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
